Evidence map›Paper›PMID 30698776›Full record

ArticleDatabase : the journal of biological databases and curation2019

Automatic identification of relevant chemical compounds from patents.

Saber A Akhondi, Hinnerk Rey, Markus Schwörer, Michael Maier, John Toomey, Heike Nau, Gabriele Ilchmann, Mark Sheehan, Matthias Irmer, Claudia Bobach and 3 more

Abstract read
In one paragraph

Article in Database : the journal of biological databases and curation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. PubChem 2023 update.Nucleic acids research · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Automatic identification of relevant chemical compounds from patents.Database : the journal of biological databases and curation · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Saber A AkhondiDepartment of Medical Informatics, Erasmus University Medical Center, Rotterdam, CA, Netherlands.
Hinnerk ReyElsevier Information Systems GmbH, Theodor-Heuss-Allee 108, Frankfurt, Germany.
Markus SchwörerElsevier Information Systems GmbH, Theodor-Heuss-Allee 108, Frankfurt, Germany.
Michael MaierElsevier Information Systems GmbH, Theodor-Heuss-Allee 108, Frankfurt, Germany.
John ToomeyElsevier Limited, 125 London Wall, London, UK.
Heike NauElsevier Information Systems GmbH, Theodor-Heuss-Allee 108, Frankfurt, Germany.
Gabriele IlchmannElsevier Information Systems GmbH, Theodor-Heuss-Allee 108, Frankfurt, Germany.
Mark SheehanElsevier Information Systems GmbH, Theodor-Heuss-Allee 108, Frankfurt, Germany.
Matthias IrmerOntoChem IT Solutions GmbH, Blücherstraße 24, Halle (Saale), Germany.
Claudia BobachOntoChem IT Solutions GmbH, Blücherstraße 24, Halle (Saale), Germany.
Marius DoornenbalElsevier B.V., Radarweg 29, Amsterdam NX, The Netherlands.
Michelle GregoryElsevier B.V., Radarweg 29, Amsterdam NX, The Netherlands.
Jan A KorsDepartment of Medical Informatics, Erasmus University Medical Center, Rotterdam, CA, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In commercial research and development projects, public disclosure of new chemical compounds often takes place in patents. Only a small proportion of these compounds are published in journals, usually a few years after the patent. Patent authorities make available the patents but do not provide systematic continuous chemical annotations. Content databases such as Elsevier's Reaxys provide such services mostly based on manual excerptions, which are time-consuming and costly. Automatic text-mining approaches help overcome some of the limitations of the manual process. Different text-mining approaches exist to extract chemical entities from patents. The majority of them have been developed using sub-sections of patent documents and focus on mentions of compounds. Less attention has been given to relevancy of a compound in a patent. Relevancy of a compound to a patent is based on the patent's context. A relevant compound plays a major role within a patent. Identification of relevant compounds reduces the size of the extracted data and improves the usefulness of patent resources (e.g. supports identifying the main compounds). Annotators of databases like Reaxys only annotate relevant compounds. In this study, we design an automated system that extracts chemical entities from patents and classifies their relevance. The gold-standard set contained 18 789 chemical entity annotations. Of these, 10% were relevant compounds, 88% were irrelevant and 2% were equivocal. Our compound recognition system was based on proprietary tools. The performance (F-score) of the system on compound recognition was 84% on the development set and 86% on the test set. The relevancy classification system had an F-score of 86% on the development set and 82% on the test set. Our system can extract chemical compounds from patents and classify their relevance with high performance. This enables the extension of the Reaxys database by means of automation.

Indexed as

Databases, ChemicalPatents as TopicData CurationData Mining

Identifiers

PMID30698776
PMCPMC6351730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.